ArticleOncotarget2017
FcGBP was upregulated by HPV infection and correlated to longer survival time of HNSCC patients.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 27 citations in OpenAlex.
- IgG Fc binding protein (FCGBP) inhibits the development of laryngeal squamous cell carcinoma and cisplatin resistance through the PIGR/JAK2/STAT3 pathway.Radiology and oncology · 2026Article
- The tumor-suppressive function of the unique H domain of FCGBP and its potential as a therapeutic target in colorectal cancer.BMC cancer · 2026Article
- FCGBP promotes ovarian cancer progression via activation of IL-6/JAK-STAT signaling pathway.Journal of translational medicine · 2025Article
- Article
- FCGBP functions as a tumor suppressor gene in head and neck squamous cell carcinoma.Discover oncology · 2024Article
- Evaluating Ovarian Cancer Chemotherapy Response Using Gene Expression Data and Machine Learning.BioMedInformatics · 2024Article
- Simulated Microgravity Influences Immunity-Related Biomarkers in Lung Cancer.International journal of molecular sciences · 2022Article
- Multi-Omics Analyses to Identify FCGBP as a Potential Predictor in Head and Neck Squamous Cell Carcinoma.Diagnostics (Basel, Switzerland) · 2022Article
- Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct.The Journal of investigative dermatology · 2022Article
- Definition of an Inflammatory Biomarker Signature in Plasma-Derived Extracellular Vesicles of Glioblastoma Patients.Biomedicines · 2022Article
- Role of the mucin-like glycoprotein FCGBP in mucosal immunity and cancer.Frontiers in immunology · 2022Review
- Salivary Trefoil Factor Family (TFF) Peptides and Their Roles in Oral and Esophageal Protection: Therapeutic Potential.International journal of molecular sciences · 2021Review
- Prognostic and immunological roles of Fc fragment of IgG binding protein in colorectal cancer.Oncology letters · 2021Article
- Trefoil Factor Family (TFF) Peptides and Their Links to Inflammation: A Re-evaluation and New Medical Perspectives.International journal of molecular sciences · 2021Review
- AKR1C3 is a biomarker and druggable target for oropharyngeal tumors.Cellular oncology (Dordrecht, Netherlands) · 2021Article
- A bioinformatic analysis: the overexpression and clinical significance of FCGBP in ovarian cancer.Aging · 2021Article
- Identification of a Novel Epithelial-Mesenchymal Transition Gene Signature Predicting Survival in Patients With HNSCC.Pathology oncology research : POR · 2021Article
- IgG Fc Binding Protein (OncoTargets and therapy · 2021Article
- Trefoil Factor Family (TFF) Peptides and Their Diverse Molecular Functions in Mucus Barrier Protection and More: Changing the Paradigm.International journal of molecular sciences · 2020Review
- Integrating proteomics and transcriptomics for the identification of potential targets in early colorectal cancer.International journal of oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
FcGBP was normally found in intestinal and colonic epithelia, gallbladder, cystic duct, bronchus, submandibular gland, cervix uteri and in fluids secreted by these cells in humans, and was down-regulated during colon carcinogenesis. We found FcGBP gene expression was decreased in HNSCC tissues compared to surgical safety border tissues while TGF-β expression level increased in HNSCC tissues, and higher FcGBP expression level was correlated to longer OS time of HNSCC patients. FcGBP expression level was higher in HPV-positive HNSCC tissues compared to HPV-negative HNSCC tissues, while TGF-β expression level was lower in HPV-positive HNSCC tissues. Gene expression level of FcGBP and TGF-β was negatively correlated in HNSCC tissues. FcGBP expression level increased after HPV E6 overexpression in HPV-negative HNSCC cells, and TGF-β could inhibit the up-regulation of FcGBP after HPV E6 or FcGBP overexpression in HPV-negative HNSCC cells. The migration capability was inhibited after FcGBP overexpression, and TGF-β could counteract the inhibition of migration caused by FcGBP overexpression. FcGBP gene expression level was correlated to the expression levels of EMT markers. In conclusion, FCGBP expression was upregulated by HPV infection while inhibited by TGF-β, and was correlated to the prognosis of HNSCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.